Global Peptide Therapy Market
Global Peptide Therapy Market

Peptide Therapy Comprehensive Study by Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, Other), Route of Administration (Parenteral, Oral, Others), Product Type (Generic, Patented), Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid Technology) Players and Region - Global Market Outlook to 2027

Peptide Therapy Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

May 2022 Edition 226 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Peptide Therapy?
Peptides, which are made up of amino acids, are the building blocks of proteins and help to regulate a range of biological functions and processes. These naturally occurring peptides work as signaling molecules in the body, directing the actions of other cells and molecules. Peptide therapies are peptides or polypeptides oligomers or short polymers of amino acids utilized for illness treatment. Peptide therapies replicate the actions of hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infective found in nature. Because peptides may be metabolized by the body, peptide Therapy is thought to be reasonably safe and well-tolerated.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAmgen Inc. (United States), Apitope International NV (Belgium), Arch Biopartners Inc. (Canada), AstraZeneca plc (United Kingdom), Circle Pharma Inc. (United States), Corden Pharma GmbH (Germany), F. Hoffmann-La Roche AG (Switzerland), Ipsen Group (France), Lonza Group AG (Switzerland) and Novo Nordisk A/S (Denmark)


The study covers a detailed analysis segmented by key business segments i.e. , by application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer and Other) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Peptide Therapy market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Peptide Therapy market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Amgen Inc. (United States), Apitope International NV (Belgium), Arch Biopartners Inc. (Canada), AstraZeneca plc (United Kingdom), Circle Pharma Inc. (United States), Corden Pharma GmbH (Germany), F. Hoffmann-La Roche AG (Switzerland), Ipsen Group (France), Lonza Group AG (Switzerland) and Novo Nordisk A/S (Denmark).

Peptides are not included in the current US Food and Drug Administration (FDA) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for pharmaceutical product quality. the New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) approval process as it relates to the quality of peptide medicines.
The peptide Therapy market is fragmented owing to the number of players present in the market. Some of the major players in the market are Eli Lilly, Novo Nordisk, Teva, and Sanofi, among others. Market leaders are investing in research and development for the production of cost-effective drugs, innovative production techniques, and growing government initiative towards developing healthcare infrastructure generating lucrative opportunities for the peptide Therapy manufacturers.

Market Trend
Rising Access To Medical Facilities and Peptides Therapies Are Used In Cosmeceutical Surgeries To Slow Down The Process Of Skin Aging
Restraints
  • Stringent Medical Norms For Medicine Manufacturing

Opportunities
Increasing Consciousness Among Individuals About Physical Appearance And The Desire To Retain Young And Healthy Skin and Development Of Automation Techniques Associated With Peptide Therapy

Key highlights of the Global Peptide Therapy market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Peptide Therapy market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Peptide Therapy market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Peptide Therapy Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Peptide Therapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Peptide Therapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Healthcare Institute, Pharmaceutical Companies, Hospitals and Clinics, Drugs Manufacturers, Research Organizations and Consulting Companies, Government Organizations, Consultants/Advisory Firms and Venture Capitalists, Private Equity Firms, and Startup Companies.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. Where the Peptide Therapy industry is heading?
Peptide Therapy Market is heading robustly to achieve new growth cycle.

2. Is Peptide Therapy market is changing from growth to value?
The Concentration Rate of Global Peptide Therapy market is dominated by United States Players and may generate healthy valuation by 2027.

3. Who are the key players profiled in the Peptide Therapy Market?
Companies that are profiled in Global Peptide Therapy Market are Amgen Inc. (United States), Apitope International NV (Belgium), Arch Biopartners Inc. (Canada), AstraZeneca plc (United Kingdom), Circle Pharma Inc. (United States), Corden Pharma GmbH (Germany), F. Hoffmann-La Roche AG (Switzerland), Ipsen Group (France), Lonza Group AG (Switzerland) and Novo Nordisk A/S (Denmark) etc.
Report Objectives / Segmentation Covered
By Application
  • Gastrointestinal Disorders
  • Neurological Disorders
  • Metabolic Disorders
  • Cancer
  • Other
By Route of Administration
  • Parenteral
  • Oral
  • Others

By Product Type
  • Generic
  • Patented

By Synthesis Technology
  • Solid Phase Peptide Synthesis
  • Liquid Phase Peptide Synthesis
  • Hybrid Technology

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Prevalence Of Acute And Chronic Diseases
      • 3.2.2. Increasing Number Of Cancer And Diabetics Mellitus Patients
    • 3.3. Market Challenges
      • 3.3.1. Production Of Cost-Effective Peptide Products
    • 3.4. Market Trends
      • 3.4.1. Rising Access To Medical Facilities
      • 3.4.2. Peptides Therapies Are Used In Cosmeceutical Surgeries To Slow Down The Process Of Skin Aging
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Peptide Therapy, by Application, Route of Administration, Product Type, Synthesis Technology and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Peptide Therapy (Value)
      • 5.2.1. Global Peptide Therapy by: Application (Value)
        • 5.2.1.1. Gastrointestinal Disorders
        • 5.2.1.2. Neurological Disorders
        • 5.2.1.3. Metabolic Disorders
        • 5.2.1.4. Cancer
        • 5.2.1.5. Other
      • 5.2.2. Global Peptide Therapy by: Route of Administration (Value)
        • 5.2.2.1. Parenteral
        • 5.2.2.2. Oral
        • 5.2.2.3. Others
      • 5.2.3. Global Peptide Therapy by: Product Type (Value)
        • 5.2.3.1. Generic
        • 5.2.3.2. Patented
      • 5.2.4. Global Peptide Therapy by: Synthesis Technology (Value)
        • 5.2.4.1. Solid Phase Peptide Synthesis
        • 5.2.4.2. Liquid Phase Peptide Synthesis
        • 5.2.4.3. Hybrid Technology
      • 5.2.5. Global Peptide Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Peptide Therapy (Price)
  • 6. Peptide Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Apitope International NV (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Arch Biopartners Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Circle Pharma Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Corden Pharma GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ipsen Group (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lonza Group AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novo Nordisk A/S (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Peptide Therapy Sale, by Application, Route of Administration, Product Type, Synthesis Technology and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Peptide Therapy (Value)
      • 7.2.1. Global Peptide Therapy by: Application (Value)
        • 7.2.1.1. Gastrointestinal Disorders
        • 7.2.1.2. Neurological Disorders
        • 7.2.1.3. Metabolic Disorders
        • 7.2.1.4. Cancer
        • 7.2.1.5. Other
      • 7.2.2. Global Peptide Therapy by: Route of Administration (Value)
        • 7.2.2.1. Parenteral
        • 7.2.2.2. Oral
        • 7.2.2.3. Others
      • 7.2.3. Global Peptide Therapy by: Product Type (Value)
        • 7.2.3.1. Generic
        • 7.2.3.2. Patented
      • 7.2.4. Global Peptide Therapy by: Synthesis Technology (Value)
        • 7.2.4.1. Solid Phase Peptide Synthesis
        • 7.2.4.2. Liquid Phase Peptide Synthesis
        • 7.2.4.3. Hybrid Technology
      • 7.2.5. Global Peptide Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Peptide Therapy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Peptide Therapy: by Application(USD Million)
  • Table 2. Peptide Therapy Gastrointestinal Disorders , by Region USD Million (2016-2021)
  • Table 3. Peptide Therapy Neurological Disorders , by Region USD Million (2016-2021)
  • Table 4. Peptide Therapy Metabolic Disorders , by Region USD Million (2016-2021)
  • Table 5. Peptide Therapy Cancer , by Region USD Million (2016-2021)
  • Table 6. Peptide Therapy Other , by Region USD Million (2016-2021)
  • Table 7. Peptide Therapy: by Route of Administration(USD Million)
  • Table 8. Peptide Therapy Parenteral , by Region USD Million (2016-2021)
  • Table 9. Peptide Therapy Oral , by Region USD Million (2016-2021)
  • Table 10. Peptide Therapy Others , by Region USD Million (2016-2021)
  • Table 11. Peptide Therapy: by Product Type(USD Million)
  • Table 12. Peptide Therapy Generic , by Region USD Million (2016-2021)
  • Table 13. Peptide Therapy Patented , by Region USD Million (2016-2021)
  • Table 14. Peptide Therapy: by Synthesis Technology(USD Million)
  • Table 15. Peptide Therapy Solid Phase Peptide Synthesis , by Region USD Million (2016-2021)
  • Table 16. Peptide Therapy Liquid Phase Peptide Synthesis , by Region USD Million (2016-2021)
  • Table 17. Peptide Therapy Hybrid Technology , by Region USD Million (2016-2021)
  • Table 18. South America Peptide Therapy, by Country USD Million (2016-2021)
  • Table 19. South America Peptide Therapy, by Application USD Million (2016-2021)
  • Table 20. South America Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 21. South America Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 22. South America Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 23. Brazil Peptide Therapy, by Application USD Million (2016-2021)
  • Table 24. Brazil Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 25. Brazil Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 26. Brazil Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 27. Argentina Peptide Therapy, by Application USD Million (2016-2021)
  • Table 28. Argentina Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 29. Argentina Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 30. Argentina Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 31. Rest of South America Peptide Therapy, by Application USD Million (2016-2021)
  • Table 32. Rest of South America Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 33. Rest of South America Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 34. Rest of South America Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 35. Asia Pacific Peptide Therapy, by Country USD Million (2016-2021)
  • Table 36. Asia Pacific Peptide Therapy, by Application USD Million (2016-2021)
  • Table 37. Asia Pacific Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 38. Asia Pacific Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 39. Asia Pacific Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 40. China Peptide Therapy, by Application USD Million (2016-2021)
  • Table 41. China Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 42. China Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 43. China Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 44. Japan Peptide Therapy, by Application USD Million (2016-2021)
  • Table 45. Japan Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 46. Japan Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 47. Japan Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 48. India Peptide Therapy, by Application USD Million (2016-2021)
  • Table 49. India Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 50. India Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 51. India Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 52. South Korea Peptide Therapy, by Application USD Million (2016-2021)
  • Table 53. South Korea Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 54. South Korea Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 55. South Korea Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 56. Taiwan Peptide Therapy, by Application USD Million (2016-2021)
  • Table 57. Taiwan Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 58. Taiwan Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 59. Taiwan Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 60. Australia Peptide Therapy, by Application USD Million (2016-2021)
  • Table 61. Australia Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 62. Australia Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 63. Australia Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Peptide Therapy, by Application USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 68. Europe Peptide Therapy, by Country USD Million (2016-2021)
  • Table 69. Europe Peptide Therapy, by Application USD Million (2016-2021)
  • Table 70. Europe Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 71. Europe Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 72. Europe Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 73. Germany Peptide Therapy, by Application USD Million (2016-2021)
  • Table 74. Germany Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 75. Germany Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 76. Germany Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 77. France Peptide Therapy, by Application USD Million (2016-2021)
  • Table 78. France Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 79. France Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 80. France Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 81. Italy Peptide Therapy, by Application USD Million (2016-2021)
  • Table 82. Italy Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 83. Italy Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 84. Italy Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 85. United Kingdom Peptide Therapy, by Application USD Million (2016-2021)
  • Table 86. United Kingdom Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 87. United Kingdom Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 88. United Kingdom Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 89. Netherlands Peptide Therapy, by Application USD Million (2016-2021)
  • Table 90. Netherlands Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 91. Netherlands Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 92. Netherlands Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 93. Rest of Europe Peptide Therapy, by Application USD Million (2016-2021)
  • Table 94. Rest of Europe Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 95. Rest of Europe Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 96. Rest of Europe Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 97. MEA Peptide Therapy, by Country USD Million (2016-2021)
  • Table 98. MEA Peptide Therapy, by Application USD Million (2016-2021)
  • Table 99. MEA Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 100. MEA Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 101. MEA Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 102. Middle East Peptide Therapy, by Application USD Million (2016-2021)
  • Table 103. Middle East Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 104. Middle East Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 105. Middle East Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 106. Africa Peptide Therapy, by Application USD Million (2016-2021)
  • Table 107. Africa Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 108. Africa Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 109. Africa Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 110. North America Peptide Therapy, by Country USD Million (2016-2021)
  • Table 111. North America Peptide Therapy, by Application USD Million (2016-2021)
  • Table 112. North America Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 113. North America Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 114. North America Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 115. United States Peptide Therapy, by Application USD Million (2016-2021)
  • Table 116. United States Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 117. United States Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 118. United States Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 119. Canada Peptide Therapy, by Application USD Million (2016-2021)
  • Table 120. Canada Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 121. Canada Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 122. Canada Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 123. Mexico Peptide Therapy, by Application USD Million (2016-2021)
  • Table 124. Mexico Peptide Therapy, by Route of Administration USD Million (2016-2021)
  • Table 125. Mexico Peptide Therapy, by Product Type USD Million (2016-2021)
  • Table 126. Mexico Peptide Therapy, by Synthesis Technology USD Million (2016-2021)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Peptide Therapy: by Application(USD Million)
  • Table 138. Peptide Therapy Gastrointestinal Disorders , by Region USD Million (2022-2027)
  • Table 139. Peptide Therapy Neurological Disorders , by Region USD Million (2022-2027)
  • Table 140. Peptide Therapy Metabolic Disorders , by Region USD Million (2022-2027)
  • Table 141. Peptide Therapy Cancer , by Region USD Million (2022-2027)
  • Table 142. Peptide Therapy Other , by Region USD Million (2022-2027)
  • Table 143. Peptide Therapy: by Route of Administration(USD Million)
  • Table 144. Peptide Therapy Parenteral , by Region USD Million (2022-2027)
  • Table 145. Peptide Therapy Oral , by Region USD Million (2022-2027)
  • Table 146. Peptide Therapy Others , by Region USD Million (2022-2027)
  • Table 147. Peptide Therapy: by Product Type(USD Million)
  • Table 148. Peptide Therapy Generic , by Region USD Million (2022-2027)
  • Table 149. Peptide Therapy Patented , by Region USD Million (2022-2027)
  • Table 150. Peptide Therapy: by Synthesis Technology(USD Million)
  • Table 151. Peptide Therapy Solid Phase Peptide Synthesis , by Region USD Million (2022-2027)
  • Table 152. Peptide Therapy Liquid Phase Peptide Synthesis , by Region USD Million (2022-2027)
  • Table 153. Peptide Therapy Hybrid Technology , by Region USD Million (2022-2027)
  • Table 154. South America Peptide Therapy, by Country USD Million (2022-2027)
  • Table 155. South America Peptide Therapy, by Application USD Million (2022-2027)
  • Table 156. South America Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 157. South America Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 158. South America Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 159. Brazil Peptide Therapy, by Application USD Million (2022-2027)
  • Table 160. Brazil Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 161. Brazil Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 162. Brazil Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 163. Argentina Peptide Therapy, by Application USD Million (2022-2027)
  • Table 164. Argentina Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 165. Argentina Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 166. Argentina Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 167. Rest of South America Peptide Therapy, by Application USD Million (2022-2027)
  • Table 168. Rest of South America Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 169. Rest of South America Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 170. Rest of South America Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 171. Asia Pacific Peptide Therapy, by Country USD Million (2022-2027)
  • Table 172. Asia Pacific Peptide Therapy, by Application USD Million (2022-2027)
  • Table 173. Asia Pacific Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 174. Asia Pacific Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 175. Asia Pacific Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 176. China Peptide Therapy, by Application USD Million (2022-2027)
  • Table 177. China Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 178. China Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 179. China Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 180. Japan Peptide Therapy, by Application USD Million (2022-2027)
  • Table 181. Japan Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 182. Japan Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 183. Japan Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 184. India Peptide Therapy, by Application USD Million (2022-2027)
  • Table 185. India Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 186. India Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 187. India Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 188. South Korea Peptide Therapy, by Application USD Million (2022-2027)
  • Table 189. South Korea Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 190. South Korea Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 191. South Korea Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 192. Taiwan Peptide Therapy, by Application USD Million (2022-2027)
  • Table 193. Taiwan Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 194. Taiwan Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 195. Taiwan Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 196. Australia Peptide Therapy, by Application USD Million (2022-2027)
  • Table 197. Australia Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 198. Australia Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 199. Australia Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Peptide Therapy, by Application USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 203. Rest of Asia-Pacific Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 204. Europe Peptide Therapy, by Country USD Million (2022-2027)
  • Table 205. Europe Peptide Therapy, by Application USD Million (2022-2027)
  • Table 206. Europe Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 207. Europe Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 208. Europe Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 209. Germany Peptide Therapy, by Application USD Million (2022-2027)
  • Table 210. Germany Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 211. Germany Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 212. Germany Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 213. France Peptide Therapy, by Application USD Million (2022-2027)
  • Table 214. France Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 215. France Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 216. France Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 217. Italy Peptide Therapy, by Application USD Million (2022-2027)
  • Table 218. Italy Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 219. Italy Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 220. Italy Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 221. United Kingdom Peptide Therapy, by Application USD Million (2022-2027)
  • Table 222. United Kingdom Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 223. United Kingdom Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 224. United Kingdom Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 225. Netherlands Peptide Therapy, by Application USD Million (2022-2027)
  • Table 226. Netherlands Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 227. Netherlands Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 228. Netherlands Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 229. Rest of Europe Peptide Therapy, by Application USD Million (2022-2027)
  • Table 230. Rest of Europe Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 231. Rest of Europe Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 232. Rest of Europe Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 233. MEA Peptide Therapy, by Country USD Million (2022-2027)
  • Table 234. MEA Peptide Therapy, by Application USD Million (2022-2027)
  • Table 235. MEA Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 236. MEA Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 237. MEA Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 238. Middle East Peptide Therapy, by Application USD Million (2022-2027)
  • Table 239. Middle East Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 240. Middle East Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 241. Middle East Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 242. Africa Peptide Therapy, by Application USD Million (2022-2027)
  • Table 243. Africa Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 244. Africa Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 245. Africa Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 246. North America Peptide Therapy, by Country USD Million (2022-2027)
  • Table 247. North America Peptide Therapy, by Application USD Million (2022-2027)
  • Table 248. North America Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 249. North America Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 250. North America Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 251. United States Peptide Therapy, by Application USD Million (2022-2027)
  • Table 252. United States Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 253. United States Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 254. United States Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 255. Canada Peptide Therapy, by Application USD Million (2022-2027)
  • Table 256. Canada Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 257. Canada Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 258. Canada Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 259. Mexico Peptide Therapy, by Application USD Million (2022-2027)
  • Table 260. Mexico Peptide Therapy, by Route of Administration USD Million (2022-2027)
  • Table 261. Mexico Peptide Therapy, by Product Type USD Million (2022-2027)
  • Table 262. Mexico Peptide Therapy, by Synthesis Technology USD Million (2022-2027)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Peptide Therapy: by Application USD Million (2016-2021)
  • Figure 5. Global Peptide Therapy: by Route of Administration USD Million (2016-2021)
  • Figure 6. Global Peptide Therapy: by Product Type USD Million (2016-2021)
  • Figure 7. Global Peptide Therapy: by Synthesis Technology USD Million (2016-2021)
  • Figure 8. South America Peptide Therapy Share (%), by Country
  • Figure 9. Asia Pacific Peptide Therapy Share (%), by Country
  • Figure 10. Europe Peptide Therapy Share (%), by Country
  • Figure 11. MEA Peptide Therapy Share (%), by Country
  • Figure 12. North America Peptide Therapy Share (%), by Country
  • Figure 13. Global Peptide Therapy share by Players 2021 (%)
  • Figure 14. Global Peptide Therapy share by Players (Top 3) 2021(%)
  • Figure 15. Global Peptide Therapy share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 19. Apitope International NV (Belgium) Revenue, Net Income and Gross profit
  • Figure 20. Apitope International NV (Belgium) Revenue: by Geography 2021
  • Figure 21. Arch Biopartners Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Arch Biopartners Inc. (Canada) Revenue: by Geography 2021
  • Figure 23. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. AstraZeneca plc (United Kingdom) Revenue: by Geography 2021
  • Figure 25. Circle Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Circle Pharma Inc. (United States) Revenue: by Geography 2021
  • Figure 27. Corden Pharma GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Corden Pharma GmbH (Germany) Revenue: by Geography 2021
  • Figure 29. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 31. Ipsen Group (France) Revenue, Net Income and Gross profit
  • Figure 32. Ipsen Group (France) Revenue: by Geography 2021
  • Figure 33. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Lonza Group AG (Switzerland) Revenue: by Geography 2021
  • Figure 35. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 36. Novo Nordisk A/S (Denmark) Revenue: by Geography 2021
  • Figure 37. Global Peptide Therapy: by Application USD Million (2022-2027)
  • Figure 38. Global Peptide Therapy: by Route of Administration USD Million (2022-2027)
  • Figure 39. Global Peptide Therapy: by Product Type USD Million (2022-2027)
  • Figure 40. Global Peptide Therapy: by Synthesis Technology USD Million (2022-2027)
  • Figure 41. South America Peptide Therapy Share (%), by Country
  • Figure 42. Asia Pacific Peptide Therapy Share (%), by Country
  • Figure 43. Europe Peptide Therapy Share (%), by Country
  • Figure 44. MEA Peptide Therapy Share (%), by Country
  • Figure 45. North America Peptide Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Amgen Inc. (United States)
  • Apitope International NV (Belgium)
  • Arch Biopartners Inc. (Canada)
  • AstraZeneca plc (United Kingdom)
  • Circle Pharma Inc. (United States)
  • Corden Pharma GmbH (Germany)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Ipsen Group (France)
  • Lonza Group AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
Additional players considered in the study are as follows:
Pfizer Inc. (United States) , Teva Pharmaceuticals Industries Ltd. (Israel) , Zealand Pharma A/S (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation